IDE Group, a leader in medical technology innovation with more than two decades of experience developing and commercialising groundbreaking medical devices, announced OKO – a revolutionary ophthalmic auto-injector.
OKO addresses critical unmet needs in ophthalmology, significantly improving drug delivery precision, procedural efficiency, and patient safety compared to existing adapted injection methods. Intravitreal injections, essential for treating retinal diseases like wet age-related macular degeneration and diabetic retinopathy, currently rely on devices originally intended for entirely different medical applications. This mismatch leads to dosing inaccuracies, procedural inefficiencies, and risks to patient safety.
IDE’s mission has always been to deliver meaningful innovations to healthcare. OKO redefines how ophthalmic drug delivery is implemented by delivering the right drug, at the right dose, precisely into the eye, ensuring therapeutic efficacy, reducing procedure complexity, and improving clinical outcomes.
OKO has been developed from extensive collaboration with ophthalmologists in Australia, the US, and Europe, highlighting IDE Group’s commitment to clinician-driven innovation. In this regard, OKO provides up to 59 times greater dosing accuracy compared to prefilled syringes, reduces procedural steps by 45%, and significantly enhances patient throughput, simultaneously cutting costs by up to 78% per injection.
Early feedback from ophthalmologists has been overwhelmingly positive, with 90% preferring OKO over conventional prefilled syringes. Pharmaceutical companies have expressed strong interest due to OKO’s capacity to differentiate their treatments and improve clinical effectiveness.
“OKO embodies IDE’s philosophy of combining ambitious innovation with practical experience,” Sokolov added. “We are committed to setting a new standard in ophthalmic care, enabling pharmaceutical companies and empowering clinicians to preserve their patients’ vision to give them a better quality of life.”
IDE Group is actively preparing OKO for market entry through strategic partnerships and comprehensive clinical validation, ensuring seamless integration into existing pharmaceutical and clinical workflows.
Learn more about IDE Group’s pioneering approach and OKO’s impact on ophthalmology:
Media Contact:
Kirsty Amland
Marketing Director
IDE Group
Phone: +61 2 9647 2660
Address: 701-703 Paramatta Rd,
Leichhardt, NSW 2040. Australia
Email: partnering@ide.group
